What's new

Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 21, Status: Authorised

Mar 28, 2025 - 15:12
 0
Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 21, Status: Authorised
Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 21, Status: Authorised
Read More

Tags:

Previous Article

Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians

Next Article

High fuel levy would avoid ‘pay-to-pollute' scenario: Maersk

Related Posts

Orphan designation: Ex-vivo-expanded autologous human corneal epithelium-containing stem cells Corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns, 07/11/2008 Expired

Orphan designation: Ex-vivo-expanded autologous human c...

Mar 7, 2025  0

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025  0

EMEA-002438-PIP02-19-M03

EMEA-002438-PIP02-19-M03

Feb 14, 2025  0